These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 34384711)

  • 21. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.
    Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A
    Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767
    [No Abstract]   [Full Text] [Related]  

  • 22. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.
    Safirstein J; Grant JJ; Clausen E; Savant D; Dezube R; Hong G
    J Cyst Fibros; 2021 May; 20(3):506-510. PubMed ID: 32736949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.
    Gramegna A; De Petro C; Leonardi G; Contarini M; Amati F; Meazza R; Carugo S; Blasi F
    J Cyst Fibros; 2022 Sep; 21(5):885-887. PubMed ID: 35450770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
    Middleton PG; Taylor-Cousar JL
    Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928
    [No Abstract]   [Full Text] [Related]  

  • 26. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 27. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
    Martin C; Reynaud-Gaubert M; Hamidfar R; Durieu I; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Lemonnier L; Burnet E; Paillasseur JL; Da Silva J; Burgel PR
    J Cyst Fibros; 2022 May; 21(3):489-496. PubMed ID: 35123901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
    Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
    [No Abstract]   [Full Text] [Related]  

  • 29. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Dooney M; Saba T
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423592
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
    Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J
    J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Burgel PR
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591
    [No Abstract]   [Full Text] [Related]  

  • 32. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare
    Burgel PR; Sermet-Gaudelus I; Girodon E; Kanaan R; Le Bihan J; Remus N; Ravoninjatovo B; Grenet D; Porzio M; Houdouin V; Le Clainche-Viala L; Durieu I; Nove-Josserand R; Languepin J; Coltey B; Guillaumot A; Audousset C; Chiron R; Weiss L; Fajac I; Da Silva J; Martin C;
    Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 38242629
    [No Abstract]   [Full Text] [Related]  

  • 33. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
    Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
    Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
    Smith S; Borchardt M
    J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
    [No Abstract]   [Full Text] [Related]  

  • 36. Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor.
    Terlizzi V; Timpano S; Salvi M; Tosco A; Castaldo A; Fevola C; Leonetti G; Vitullo P; Sepe A; Badolato R; Salvatore D
    J Cyst Fibros; 2023 Nov; 22(6):1130-1132. PubMed ID: 37400299
    [No Abstract]   [Full Text] [Related]  

  • 37. Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis.
    Lee TWR; Duff AJA
    Am J Respir Crit Care Med; 2024 Feb; 209(3):239-241. PubMed ID: 38113403
    [No Abstract]   [Full Text] [Related]  

  • 38. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.
    Causer AJ; Shute JK; Cummings MH; Shepherd AI; Wallbanks SR; Pulsford RM; Bright V; Connett G; Saynor ZL
    Pediatr Pulmonol; 2022 Nov; 57(11):2652-2658. PubMed ID: 35851858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy.
    Manciulli T; Bresci S; Mencarini J; Avarello A; Taccetti G; Terlizzi V
    Pediatr Pulmonol; 2023 Dec; 58(12):3626-3629. PubMed ID: 37750598
    [No Abstract]   [Full Text] [Related]  

  • 40. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
    Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
    Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.